80
Participants
Start Date
February 28, 2007
Primary Completion Date
May 31, 2010
Study Completion Date
May 31, 2010
Gonal F
"* 450 IU Gonal-f (Serono Canada) subcutaneously daily (225 IU BID; injections to be given after bloodwork).~* Dosing to begin on day 1 or day 4 (day 1=first day of menses), continuing until administration of human Chorionic Gonadotropin (hCG; see below).~* Gonal-f dose may be further reduced, at the discretion of the study physician, to minimize the risk of OHSS."
Luveris
"* 0.250 mg Cetrotide (Serono Canada) and 75 IU Luveris (Serono Canada) subcutaneously daily when one or more of the following conditions are met:~ * leading follicle is \> 13 mm in diameter~ * if 6 or more follicles develop to \> 10 mm and E2 \> 1000 pmol/L~* Dosing to continue until administration of hCG (see below)."
Cetrotide
"* 0.250 mg Cetrotide (Serono Canada) and 75 IU Luveris (Serono Canada) subcutaneously daily when one or more of the following conditions are met:~ * leading follicle is \> 13 mm in diameter~ * if 6 or more follicles develop to \> 10 mm and E2 \> 1000 pmol/L~* Dosing to continue until administration of hCG (see below)."
hCG
"\- 10,000 IU hCG (Pharmaceutical Partners of Canada Inc.) subcutaneously when:~o \> 3 follicles are \> 17 mm in diameter"
Genesis Fertility Centre, Vancouver
Department of Obstetrics, Gynecology and Reproductive Sciences, University of Saskatchewan, Saskatoon
Royal University Hospital Foundation
OTHER
University of Saskatchewan
OTHER